Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia

Severa Bunda¹, Michelle W. Kang³, Stephanie S. Sybingco¹, Julie Weng³, Helene Favre³, Danielle H. Shin³, Meredith S. Irwin⁷, Mignon L. Loh⁷,⁴, and Michael Ohh¹

Abstract

Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm in children characterized by the overproduction of monocytic cells that infiltrate the spleen, lung, and liver. JMML remains a disease for which few curative therapies are available other than myeloablative hematopoietic stem cell transplant (HSCT); however, relapse remains a major cause of treatment failure and the long-term morbidities of HSCT for survivors are substantial. A hallmark feature of JMML is acquired hypersensitivity by clonal myeloid progenitor cells to granulocyte macrophage-colony stimulating factor (GM-CSF) via a largely unknown mechanism. Here, we identify c-Cbl (henceforth referred to as Cbl) as a GM-CSF receptor (GMR) adaptor protein that targets Src for ubiquitin-mediated destruction upon GM-CSF stimulation and show that a loss of negative regulation of Src is pivotal in the hyperactivation of GMR signaling in Cbl-mutated JMML cells. Notably, dasatinib, an U.S. Food and Drug Administration–approved multikinase inhibitor that also targets Src family, dramatically attenuated the spontaneous and GM-CSF-induced hypersensitive growth phenotype of mononuclear cells from peripheral blood and bone marrow collected from JMML patients harboring Cbl or other known JMML-associated mutations. These findings reveal Src kinase as a critical oncogenic driver underlying JMML. Cancer Res; 73(8): 2540–50. ©2013 AACR.

Introduction

The majority of juvenile myelomonocytic leukemia (JMML)–associated mutations have been mapped to genes that encode proteins that signal through the Ras/mitogen-activated protein kinase (MAPK) pathway, including NF1, NRAS, KRAS, and PTPN11 (SH2B2), which account for approximately 75% of JMML patients (1). Recently, we identified Casitas B-lineage Lymphoma (CBL) mutations that were reduced to homozygosity in approximately 10–15% of children with JMML (2, 3), thereby establishing CBL as a new JMML tumor suppressor gene. Importantly, CBL mutations in JMML patient samples were mutually exclusive with respect to other Ras pathway-associated mutations but nevertheless displayed the classic granulocyte macrophage-colony stimulating factor (GM-CSF) hypersensitivity phenotype, which suggests a possible convergence of Cbl and Ras signaling pathways. Consistent with this notion, CBL mutations have been confirmed in other Ras-related disorders, Noonan syndrome (4), as well as in myelodysplastic syndromes, atypical chronic myelogenous leukemia and chronic myelomonocytic leukemia, diseases that primarily occur in adults that share some clinical and molecular features with JMML (5–7).

Cbl is a RING-type E3 ubiquitin ligase that ubiquitylates receptor and non-receptor tyrosine kinases (8). Cbl contains a highly conserved N-terminal tyrosine kinase-binding (TKB) domain that mediates interaction between Cbl and phosphorylated tyrosines on activated receptor tyrosine kinases such as epidermal growth factor receptor (EGFR; ref. 9), platelet-derived growth factor receptor (PDGFR; ref. 10) and c-Kit (11), as well as non-receptor tyrosine kinases JAK2, ZAP-70, and Syk (12). The RING finger is separated from the TKB domain by an alpha helical structure known as the linker region, which is critical for the regulation of E3 function (13). Crystallographic study has revealed that the linker region contacts the TKB domain, the RING finger, and the E2 ubiquitin-conjugating enzyme (14). Y371 within the linker region becomes phosphorylated upon interaction with tyrosine kinases such as EGFR and insulin receptor, leading to conformational change in Cbl and activation of its E3 activity (13). Moreover, C-terminal to the RING finger is a proline-rich domain that mediates interaction with SH3-containing and SH2 proteins such as the p85 subunit of PI3K (15). Notably, although Cbl’s E3 function serves as a negative regulator of signaling, its role as an adaptor molecule potentiates signal...
transduction (13). We and others have recently showed that JMML-associated CBL mutations, including the most common Y371H substitution, result in the loss of E3 function (3, 7). Although these studies have provided important insights into the possible consequences of CBL mutations, the mechanisms responsible for the GM-CSF hypersensitivity phenotype invariably displayed by JMML progenitor cells remains largely unknown.

Materials and Methods

Cells

HEK293 and TF-1 cells were obtained from the American Type Culture Collection. HEK293 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Wisent) at 37°C in a humidified 5% CO2 atmosphere. TF-1 cells were maintained similarly in RPMI-1640 (Wisent) medium supplemented with 10% FBS and 2 ng/mL GM-CSF (Invitrogen).

Retroviral production and BaF3-GMR cell generation

GM-receptor α (GMα) and GMβc were subcloned into pRUFneocIRES retroviral expression system (pRUFneocIRES-GMα/βc) and cotransfected with pEQEco packaging plasmid (both generous gifts from Dr. Tim Hercus; Centre for Cancer Biology, Adelaide, Australia) into HEK293 cells. The media was replaced with fresh media the next day. Viral supernatant was harvested 2 and 3 days posttransfection and passed through a 0.45 μm filter (Pall). BaF3-HA-Cbl (WT, Y371H, 70Z) cells were generated as previously described (6), maintained in RPMI-1640 (Wisent) medium supplemented with 10% FBS and 2 ng/mL GM-CSF (Invitrogen).

Generation of shCbl and ShLyn cell lines

TF-1-shCbl and TF-1-shScr cells were generated using SMARTvector 2.0 Lentiviral shRNA particles targeted against human Cbl (Dharmacon). Cell populations with stable Cbl knockdown were selected with puromycin, sorted on a FACS Aria (BD Biosciences) and further confirmed by Western blot analysis. The stable cell lines were maintained in RPMI-1640 medium with 10% FBS, 2 ng/mL GM-CSF, 10 ng/mL puromycin, and 0.25 mg/mL G418.

Antibodies

Rabbit polyclonal antibodies against Cbl, pCblY774, Lyn, Src, phosphorylated (p)Src(Y416) as well as Src phosphorylated on Y527, YAK2, pYAK2, pSTAT5, and STAT5 were obtained from Cell Signalling Technologies. Antibodies against GMα, GMβc (monoclonal and polyclonal), Cbl (monoclonal), and polyclonal extracellular signal-regulated kinase (pERK) were obtained from Santa Cruz Biotechnology. Monoclonal antibodies against HA (12CA5), pTYR (4G10), and ubiquitin were obtained from Boehringer Ingelheim, Millipore, and Dako, respectively. Monoclonal β-actin and pERK antibodies were obtained from Sigma.

Plasmids

Plasmids encoding pDEST40-HA-Cbl (WT, Y371H, 70Z) were generated as previously described (3), pSG5-GMα and pSG5-GMβc constructs were also generously provided by Dr. Tim Hercus. All constructs were verified by direct DNA sequencing.

Ssrc knockdown via siRNA

Endogenous Src in HEK293 cells was silenced using ON-TARGETplus SMARTpool siRNA (Dharmacon) according to the manufacturer's instructions.

Immunoprecipitation and immunoblotting

Immunoprecipitation and Western blotting were done as described previously (16).

Chemicals

Dasatinib, cycloheximide, AG490, and PP2 were obtained from Sigma. MG132 was obtained from Peptides International.

Primary patient studies

Sample collection. Bone marrow or peripheral blood samples were collected from children suspected of having JMML. The UCSF Committee on Human Research approved this study. All samples were obtained with informed consent. Mononuclear cells were isolated according to standard procedures. Genomic DNA was isolated using Puregene reagents (Qiagen). Patients were genotyped for mutations in PTEN exons 3 and 13, NRAS/KRAS exons 1 and 2, and CBL exons 8 and 9 according to previously reported methods (2, 17–19).

Human hematopoietic progenitor assays. In CFU-GM assays, mononuclear cells from peripheral blood or bone marrow were plated in MethoCult H4230 (StemCell Technologies) and supplemented with recombinant human GM-CSF (Peprotech). Colonies were counted after 14 days, as previously described (20). For CFU-GM assays in which cells were exposed to dasatinib (LC Laboratories) or imatinib (LC Laboratories), inhibitor was diluted in dimethyl sulfoxide (DMSO) and directly added to the MethoCult before plating.

Western blots. Mononuclear cells were rested for 30 minutes in Iscove's Modified Dulbecco's Medium and 1% bovine serum albumin followed by exposure to inhibitor for 30 minutes. Cells were stimulated with 10 ng/mL recombinant human GM-CSF (Peprotech) for 15 minutes. Resting, inhibitor exposure, and stimulation were all done at 37°C, 5% CO2. Whole lysates were prepared, resolved on SDS-PAGE and...
immunoblotted with the indicated antibodies as previously described (20).

**Statistical analyses**

Unpaired 2-tailed Student’s t test was used to compare between treatment groups and cell types. All statistical analysis was done using GraphPad PRISM 5.0 software. Statistical significance was achieved at the confidence limit indicated.

**Results**

GMR is composed of a ligand-specific α chain (GMRα) and the β common (GMRβc) signaling subunit, which is shared with the IL-3 and IL-5 receptors (21). Upon binding of GM-CSF to GMRα, a higher-order signaling complex is formed that promotes the activation of nonreceptor tyrosine kinases JAK2 and Src family kinases c-Src and Lyn, which subsequently phosphorylate GMRβc (22). Activated GMR serves as a docking site for adaptors and signaling molecules resulting in activation of downstream signaling, including the ERK pathway (23). However, the role of Cbl in GMR-mediated signaling has been unexplored.

To begin addressing this question, we first asked whether phosphorylation of Cbl is associated with GMR activation. GM-CSF treatment of serum-starved human myeloid TF-1 cells, which are dependent on GM-CSF for growth and survival (24), promoted phosphorylation of endogenous Cbl in a manner temporally similar to the phosphorylation pattern of GMRβc (Fig. 1A and Supplementary Fig. S1). Importantly, endogenous Cbl coprecipitated with endogenous GMRβc and GMRα in the presence of GM-CSF in TF-1 cells (Fig. 1B and data not shown). In addition, murine pro-B BaF3 cells, which were previously transduced with shRNA against endogenous murine Cbl (3),...
were stably reconstituted with ectopic GMR and endogenous level of HA-tagged human Cbl(WT or Y371H). Consistent with TF-1 results, ectopic GMR\textsubscript{bc} associated with HA-Cbl(WT) and, as expected, GMR\textsubscript{ax} in the presence of GM-CSF (Fig. 1B). These results show for the first time that Cbl is in a complex with GMR preferentially upon GM-CSF stimulation.

In comparison to Cbl(WT), the JMML-associated Cbl (Y371H) mutant showed markedly increased binding to GMR\textsubscript{bc} in both BaF3-GMR cells and human embryonic kidney epithelial HEK293 cells ectopically expressing GMR\textsubscript{ax}/\textsubscript{bc} in combination with HA-Cbl(WT or Y371H; Fig. 1C and D), which suggest that Cbl(Y371H) mutant binds to GMR\textsubscript{bc} with greater

Figure 2. Cbl(Y371H) and the associated GMR\textsubscript{bc} show hyperphosphorylation profile following GM-CSF stimulation. A. BaF3-GMR-HA-Cbl(WT or Y371H) cells (left) or HEK293 cells transfected with the indicated plasmids (right) were serum/cytokine starved for 18 hours and treated with (+) or without (-) 1 ng/mL of GM-CSF for 10 minutes. The cells were lysed, immunoprecipitated with anti-GMR\textsubscript{bc} or anti-HA antibody, and immunoblotted with anti-pTyr antibody. B, serum/cytokine-starved BaF3-GMR-HA-Cbl(WT or Y371H) cells treated for 10 minutes with indicated concentrations of GM-CSF were lysed and immunoblotted with the indicated antibodies. WCE, whole cell extract; IP, immunoprecipitation.
affinity than Cbl(WT). Notably, HA-Cbl(Y371H) phosphorylation level was substantially higher than that of HA-Cbl(WT) even in the absence of GM-CSF stimulation (Fig. 2A). Following GM-CSF stimulation, expression of HA-Cbl(Y371H) promoted GMRβc hyper-phosphorylation (Fig. 2A). These results suggest that the amino acid Y371H substitution exaggerates mutant Cbl and also GMRβc activation. In an effort to define the mechanism responsible for the hyper-phosphorylation of Cbl(Y371H) and the associated GMRβc, we next examined the signaling events downstream of GMR. Consistent with the
Cbl(Y371H) hyper-phosphorylation is Src-dependent. HEK293 cells transfected with the indicated plasmids pretreated with 100 nmol/L of dasatinib (+) or DMSO (−) for 1 hour and treated with (+) or without (−) 1 ng/mL of GM-CSF for 10 minutes were lysed, immunoprecipitated with anti-HA antibody (A) or anti-GMRβc antibody (B), and immunoblotted with indicated antibodies. C, BaF3-GMR-HA-Cbl(WT or Y371H) cells were serum/cytokine starved for 18 hours and then pretreated with 5 mmol/L of AG490, 100 nmol/L of dasatinib (+), or DMSO (−) for 1 hour and treated for 10 minutes with (+) or without (−) 1 ng/mL of GM-CSF for 10 minutes. Cells were then lysed, immunoprecipitated with anti-HA antibody, and immunoblotted with indicated antibodies. D, BaF3-GMR-HA-Cbl(WT or Y371H) cells were serum/cytokine starved for 18 hours and then pretreated with 10 mmol/L of PP2 (+) or DMSO (−) for 1 hour and treated for 10 minutes with (+) or without (−) 1 ng/mL of GM-CSF, lysed, immunoprecipitated with anti-HA antibody, and immunoblotted with anti-pTyr antibody. E, BaF3-GMR : Cbl(Y371H) cells transduced with anti-shScrambled or anti-shLyn (shLyn) were serum/cytokine starved for 18 hours and treated with (+) or without (−) 1 ng/mL of GM-CSF, lysed, immunoprecipitated with anti-HA-Cbl antibody, and immunoblotted with anti-pTyr antibody. Equal amounts of corresponding cell lysate were immunoblotted with indicated antibodies. F, HEK293 cells transfected with c-Src-specific siRNA (si-c-Src) or a nontargeting scrambled siRNA (si-Con) in combination with the indicated plasmids were treated with (+) or without (−) 1 ng/mL of GM-CSF for 10 minutes. Cells were then lysed, immunoprecipitated with anti-HA antibody, and immunoblotted with indicated antibodies. G, HEK293 cells transfected with c-Src-specific siRNA (si-c-Src) or a nontargeting scrambled siRNA (si-Con) in combination with the indicated plasmids were lysed, immunoprecipitated with anti-GMRβc antibody, and immunoblotted with indicated antibodies. WCE, whole cell extract; IP, immunoprecipitation.
Figure 5. Dasatinib inhibits CFU-GM growth in primary JMML cells harboring CBL or Ras pathway mutations. A, individual JMML patient-derived leukemic cells with the indicated mutations (see Supplementary Table S1) were exposed to dasatinib (150 nmol/L) in the absence or presence of GM-CSF (10 ng/mL). Percentage of maximum colony growth is graphed in relation to 0 nmol/L dasatinib at 10 ng/mL of GM-CSF. The indicated n represents the number of patients analyzed for each mutation group. The lighter shaded bars represent vehicle-treated groups and the darker shaded bars represent dasatinib-treated groups. Error bars indicate SEM. B, cell number per colony and cell size plated from a patient harboring a Cbl(Y371H) mutation significantly decreased in the presence of dasatinib with and without GM-CSF. Colonies were visualized at a total magnification of $\times 40$ on a 2-mm-gridded dish.
hypersensitive GM-CSF phenotype previously reported for JMLL progenitors with the Cbl(Y371H) mutation (3). BaF3-GMR-Cbl(Y371H) cells displayed elevated STAT5 and ERK phosphorylation upon exposure to a range of GM-CSF concentrations compared to BaF3-GMR-Cbl(WT) cells (Fig. 2B). Perhaps most importantly, the basal as well as GM-CSF-stimulated Src phosphorylation on Y416, representing activated Src (25), were markedly increased in BaF3-GMR-Cbl(Y371H) cells (Fig. 2B).

Yokuchi and colleagues (26) previously showed that Src phosphorylates Cbl, which triggers its E3 ligase function, including ubiquitin-mediated degradation of Src as a negative activity. We previously showed that the loss of E3 activity prolonged the turnover rate of Cbl(Y371H) because of a failure in ubiquitin-mediated autodestruction (3). Therefore, we asked whether the loss of E3 activity via the acquisition of Y371H mutation results in the loss of negative regulation of Src and the perpetuation of Cbl(Y371H) and Src activation in the context of GMR signaling. GM-CSF treatment of serum/cytokine-starved TF-1 cells enhanced Src phosphorylation and subsequent signaling (22), bound Cbl preferentially in the presence of GM-CSF (Fig. 3A, right). These results show for the first time that Cbl associates with Src, in particular Lyn, in the context of GMR activation in myeloid cells.

Inhibition of Src activity via a specific Src kinase inhibitor, PP2, as well as an U.S. Food and Drug Administration (FDA)-approved Abl and Src tyrosine kinase inhibitor, dasatinib, abolished Src phosphorylation, and dramatically reduced GM-CSF-induced Cbl and GMRCbl phosphorylation (Fig. 3B and C), which support the notion that Src is critical in regulating the activity of Cbl and GMR following GM-CSF stimulation. Moreover, endogenous Cbl knockdown in TF-1 cells using CBL-specific lentivirus-shRNA, but not the non-targeting scrambled lentivirus-shRNA, enhanced Src and GMRCbl phosphorylation, and prolonged Src turnover upon GM-CSF stimulation (Fig. 3D and E). Furthermore, Cbl(WT), but not Cbl(Y371H), promoted GM-CSF–induced Src ubiquitylation and clearance (Fig. 3F and G). These results suggest that JMLL-associated Y371H mutation abrogates Cbl-mediated ubiquitylation and subsequent degradation of Src upon GMR activation. In addition, pharmacologic inhibition of Src using dasatinib or PP2 dramatically attenuated hyper-phosphorylation of Cbl(Y371H) and GMRCbl upon GM-CSF stimulation (Fig. 4A–D). The heightened phosphorylation of Cbl(Y371H) in the absence of ligand was likewise abrogated in the presence of dasatinib or PP2 (Fig. 4A, C, and D). Consistent with these observations, shRNA-mediated knockdown of Lyn in BaF3-GMR cells markedly attenuated Cbl(Y371H) phosphorylation, as well as the level of phosphorylated ERK, in the presence or absence of GM-CSF (Fig. 4E). Notably, siRNA-mediated knockdown of c-Src in HEK293 cells not only suppressed Cbl(Y371H) phosphorylation, but also attenuated the association between Cbl (Y371H) and GMR(bc) (Fig. 4F and G). It should be noted that a highly specific JAK2 inhibitor, AG490, effectively blocked JAK2 phosphorylation, but did not attenuate Src phosphorylation and failed to inhibit Cbl(Y371H) hyper-phosphorylation upon GM-CSF stimulation (Fig. 4C). These results show that the binding of Cbl to GMR(bc) as well as phosphorylation of Cbl upon GMR activation is dependent on Src, and that JMLL-associated Cbl(Y371H) prolongs hyperactivation of GMR-mediated signaling because of a failure in the Cbl-mediated negative regulation of Src.

We next exposed freshly isolated mononuclear cells from peripheral blood and bone marrow collected from multiple JMLL patients with confirmed CBL mutation (or canonical Ras pathway alteration, including NFI, NRAS, and PTPN11 mutations) to increasing doses of dasatinib in colony-forming unit-granulocyte macrophage (CFU-GM) assay (Fig. 5A and Supplementary Table S1). Notably, dasatinib is a multi-kinase inhibitor that targets Src family kinases, BCR-ABL, PDGFRα, and KIT, among others, and is an FDA approved agent commonly used in the treatment of patients with BCR-ABL positive chronic myelogenous leukemia (CML) or in combination with chemotherapy in Ph+ acute lymphoblastic leukemia. Importantly, it is a well-tolerated oral agent with an established toxicity profile published not only in adults but also in children (28, 29) and can be administered as a liquid suspension to young patients incapable of swallowing pills. Strikingly, all tested JMLL cells irrespective of mutational status showed substantial inhibition of spontaneous growth in the presence of dasatinib concentrations as low as 10 nmol/L, whereas approximately 50% inhibition at doses of 50 nmol/L or higher was observed in the presence of saturating GM-CSF (Fig. 5A and Supplementary Fig. S2A and S3A). In addition to the diminution in colony number, the size of the colonies was also dramatically reduced in the presence of dasatinib or without GM-CSF irrespective of mutational status (Fig. 5B and Supplementary Fig. S2B). Exposing cells to dasatinib at a concentration achievable in patients taking the oral drug (150 nmol/L) shifted the GM-CSF hypersensitivity curve back to a more normal appearance (Fig. 5C). In primary peripheral blood mononuclear cells harboring Cbl(Y371H), Cbl intron 8 deletion, PTPN11 (E76V), N-Ras(G12D), or NFI LOH, dasatinib treatment, which predictably attenuated phosphorylated (p)Src levels,
dramatically reduced pERK levels in the presence of saturating doses of GM-CSF (Fig. 5D and E and Supplementary Fig. S4). In contrast, imatinib, an Abl-specific inhibitor that does not target Src, had no discernable effect on pSrc or pERK levels or on the hypersensitive colony growth (Fig. 5D and Supplementary Fig. S3B). These results suggest that pharmacologic inhibition of Src attenuates GM-CSF hypersensitivity of peripheral bone and bone marrow–derived primary JMML cells in a dosage-dependent manner.

Discussion

Recently, we and others identified sporadic and germline CBL mutations in JMML patients with Y371H mutation emerging as the most common CBL mutation (3, 7). Although mutations in Cbl were predicted to result in the loss of E3 function (3, 7), the molecular mechanism by which these mutations cause JMML and more precisely the observed GM-CSF hypersensitivity that underlies JMML remained unclear. Here, we show that Cbl binds to ligand-engaged GMR in a Src-dependent manner and targets Src for ubiquitin-mediated destruction. In comparison to wild-type Cbl, Cbl(Y371H) exhibited increased affinity for activated GMR complex and failed to ubiquitylate active Src, thereby causing accumulation of p Src. Conformational change of Cbl structure because of gene mutation likely altered the binding affinity of Cbl(Y371H) to GMRβc. The interaction between Cbl and GMRβc is, however, also influenced by GMR activation in the presence of GM-CSF, which raises the possibility that the consequent phosphorylation of Cbl and/or GMRβc promotes their physical association. Notably, Cbl and GMRβc association and phosphorylation in the presence of GM-CSF are, at least in part, dependent on Src. These observations suggest that in addition to gene mutation-induced conformational changes, Src-dependent phosphorylation contributes to Cbl binding to GMRβc. Src has been shown to activate and phosphorylate Cbl on multiple tyrosine residues, including Y700, 731, and 774, which promote several signaling cascades (30). Src also phosphorylates Cbl on Y371 to activate the E3 ligase function of Cbl, which in turn trigger interdependent ubiquitylation and degradation of both proteins (26), a process necessary for terminating downstream signaling postactivation. Consistent with this notion, the pathological stabilization of pSrc resulted in Src-dependent hyper-phosphorylation and concomitant stabilization of Cbl(Y371H) upon GM-CSF stimulation to accentuate and prolong GMRβc phosphorylation and downstream signaling. These lines of evidence suggest that the critical loss of negative regulation of Src upon JMML–causing CBL mutations underlies GM-CSF hypersensitivity.

Despite the fact that IL-3 and IL-5 also associate with β common subunit (i.e., GMRβc; ref. 21), JMML cells do not display hypersensitivity to IL-3 or IL-5. Notably, Src binds to the ligand–specifying GMα chain, which upon ligand binding associates with GMRβc to initiate GMRβc activation via JAK2 and Src (22, 31). However, it is unclear whether IL-3R or IL-5R directly interacts Src or Cbl and whether the interplay observed between Cbl and Src on GMR is recapitulated on IL-3/5R. For example, IL-3 treatment was previously shown to increase the amount of Grb2 associated with Cbl; however, it did not alter the level of Fyn (another member of Src kinase family) associated with Cbl (32). Consistent with these uncertainties, IL-3 treatment did not differentially influence IL-3–mediated signaling in BaF3-Cbl(Y371H) cells in comparison to wild-type Cbl-expressing BaF3 cells (data not shown). These observations underscore the importance of Src interaction on GMRα in promoting GM-CSF hypersensitivity observed in cells harboring Cbl(Y371H) mutation.

Perhaps most importantly, dasatinib dramatically attenuated spontaneous and GM-CSF-dependent hypersensitive growth phenotype of human primary leukemic cells collected from peripheral blood or bone marrow of JMML children harboring Cbl mutations. Notably, imatinib, an Abl-specific inhibitor that does not target Src, had no appreciable effect on pSrc or pERK levels or on the hypersensitive colony growth of JMML cells. Intriguingly, dasatinib also reduced the hypersensitive growth phenotype of JMML cells harboring Ras pathway mutations (see Fig. 5A, E, Supplementary Fig. 2 and 4), which suggests potential involvement of Src in non-Cbl mutated JMML cells. Although the connection between Ras pathway and Src in the context of GM-CSF–mediated signaling has not been formally established, a biochemical link between Src and Ras has been speculated through the interaction via Raf-1 (33). Recently, the expression of oncogenic Ras has been shown to induce c-Src activation, and elevated Src activity has been observed in human cancer cell lines that harbor oncogenic Ras mutations (34) as well as in pancreatic ductal adenocarcinoma that are characterized with a high incidence of oncogenic K-Ras mutations (35). Interestingly, G proteins are GTPases that have also been shown to directly activate Src (36). Thus, it remains to be determined whether oncogenic Ras, which is also a GTPase, drives Src activity via Raf-1 or yet-defined mediator protein(s) to influence Cbl-dependent GMR signaling. Undefined connection between Ras pathway and Src notwithstanding, these results suggest that the loss of negative regulation of Src in certain susceptible myeloid progenitor population is central to the GM-CSF hypersensitivity phenotype invariably observed in JMML patients, and that Src represents a potential druggable target for the amelioration of the hypersensitive growth phenotype of primary human JMML cells. Despite the promise of dasatinib, it is a multi-kinase inhibitor, and hence the future challenge would be to develop small molecular inhibitors that exclusively target Src ideally in leukemic progenitors in JMML patients.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: S. Bunda, M.S. Irwin, M.L. Loh, M. Ohh

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Bunda, M.W. Kang, S.S. Sybingco, J. Weng, H. Favre, M.L. Loh

Analysis and interpretation of data (e.g., statistical analysis, bioinformatics, computational analysis): S. Bunda, M.W. Kang, S.S. Sybingco, J. Weng, H. Favre, M.S. Irwin, M.L. Loh, M. Ohh

Development of methodology: S. Bunda

Other: Authors specifically contributed to the following areas of research:

- Experimental design and data analysis (S. Bunda, M.W. Kang, S.S. Sybingco, J. Weng, H. Favre, M.L. Loh)

Favre, M.S. Irwin, M.L. Loh, M. Ohh

Bunda et al.
Writing, review, and/or revision of the manuscript: S. Bunda, M.W. Kang, M. S. Irwin, M.L. Loh, M. Ohh
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.W. Kang, D.H. Shin, M.L. Loh.
Study supervision: M.L. Loh, M. Ohh

Acknowledgments

We thank Dr. Benjamin S. Braun for his helpful comments and discussions. We also thank Dr. Tim Herges for his helpful suggestions and providing GMR reagents. S. Bunda is a recipient of the CIHR and Kidney Cancer Foundation fellowship award. M.L. Loh is a Clinical Scholar of the Leukaemia Lymphoma Society.

References


Grant Support

This work was supported by grants from the Canadian Institutes of Health Research (CIHR; MOP193536; M. Ohh), Cancer Research Society (M. Ohh), the Leukaemia Lymphoma Society Translational Research Program (M.L. Loh), and the Frank A. Campini Foundation (M.L. Loh).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 28, 2012; revised January 11, 2013; accepted January 16, 2013; published OnlineFirst February 11, 2013.
33. Williams NG, Roberts TM, Li P. Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. Proc Natl Acad Sci U S A 1992;89:2922–6.


Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia

Severa Bunda, Michelle W. Kang, Stephanie S. Sybingco, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-3425

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/02/11/0008-5472.CAN-12-3425.DC1

Cited articles
This article cites 36 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/8/2540.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/73/8/2540.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/73/8/2540.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.